The guidelines called for Phase 3 studies to include a two-month follow-up period to see whether participants reported any serious side effects. Peter Marks, the director of the Center for Biologics Evaluation and Research at the FDA, had a PhD in cell and molecular biology and was working arm in arm with Hahn on the approval process.
